Literature DB >> 20962525

Viral load and CD4+ cell count as risk factors for prolonged QT interval in HIV-infected subjects: a cohort-nested case-control study in an outpatient population.

Ashraf Y Qaqa1, Hamid Shaaban, Vincent A DeBari, Suzan Phung, Jihad Slim, Constantinos A Costeas, George Perez, Fayez E Shamoon.   

Abstract

BACKGROUND: QTc interval prolongation is a serious ECG finding which has frequently been reported in HIV-infected patients, but associated risk factors have not been determined in this population.
METHODS: Data were collected from the charts of a cohort of 135 consecutive HIV-infected patients from our HIV outpatient clinic. The cohort was divided into two groups, patients with prolonged QTc and those with normal QTc interval. Multiple variables and potential risk factors were analyzed, including the CD4+ cell count and viral load (VL), which were assessed on the same day or within several days of the initial ECG.
RESULTS: 23 patients were found to have prolonged QTc (17%). No significant difference in baseline characteristics was observed between the groups; however, statistically significant differences were observed with regard to the CD4+ cell count and VL.
CONCLUSION: A low CD4 cell count and a high VL may be risk factors potentially related to QT prolongation in HIV patients in the outpatient setting.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20962525     DOI: 10.1159/000320216

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  5 in total

1.  Reduced functional connectivity between ventromedial prefrontal cortex and insula relates to longer corrected QT interval in HIV+ and HIV- individuals.

Authors:  Roger C McIntosh; Dominic C Chow; Corey J Lum; Melissa Hidalgo; Cecilia M Shikuma; Kalpana J Kallianpur
Journal:  Clin Neurophysiol       Date:  2017-07-25       Impact factor: 3.708

2.  Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Authors:  Gerald S Bloomfield; Isabelle R Weir; Heather J Ribaudo; Kathleen V Fitch; Carl J Fichtenbaum; Laura E Moran; Roger Bedimo; Christopher de Filippi; Caryn G Morse; Jonathan Piccini; Markella V Zanni; Michael T Lu; Udo Hoffmann; Steven K Grinspoon; Pamela S Douglas
Journal:  J Acquir Immune Defic Syndr       Date:  2022-03-01       Impact factor: 3.771

3.  Effect of left ventricular dysfunction and viral load on risk of sudden cardiac death in patients with human immunodeficiency virus.

Authors:  Brian S Moyers; Eric A Secemsky; Eric Vittinghoff; Joseph K Wong; Diane V Havlir; Priscilla Y Hsue; Zian H Tseng
Journal:  Am J Cardiol       Date:  2014-01-16       Impact factor: 2.778

Review 4.  Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.

Authors:  Shubham Agarwal; Sanjeev Kumar Agarwal
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-12       Impact factor: 3.727

5.  Association between exposure to Efavirenz and substrates of dysrhythmia in HIV-infected young adults.

Authors:  Zahra Hosseini; Reza Mollazadeh; Seyed-Ali Dehghan-Manshadi; Mehrnaz Mohebi; Masoud Eslami; Seyed-Ali Sadre-Bafghi; Ali Akbari; Saeed Ghodsi
Journal:  Clin Cardiol       Date:  2021-07-30       Impact factor: 2.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.